|
1
|
Lim SS, Davies MJ, Norman RJ and Moran LJ:
Overweight, obesity and central obesity in women with polycystic
ovary syndrome: A systematic review and meta-analysis. Hum Reprod
Update. 18:618–637. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pasquali R: Obesity and androgens: Facts
and perspectives. Fertil Steril. 85:1319–1340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cattrall FR and Healy DL: Long-term
metabolic, cardiovascular and neoplastic risks with polycystic
ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 18:803–812.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lass N, Kleber M, Winkel K, Wunsch R and
Reinehr T: Effect of lifestyle intervention on features of
polycystic ovarian syndrome, metabolic syndrome and intima-media
thickness in obese adolescent girls. J Clin Endocrinol Metab.
96:3533–3540. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Crosignani PG, Colombo M, Vegetti W,
Somigliana E, Gessati A and Ragni G: Overweight and obese
anovulatory patients with polycystic ovaries: Parallel improvements
in anthropometric indices, ovarian physiology and fertility rate
induced by diet. Hum Reprod. 18:1928–1932. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thomson RL, Buckley JD, Noakes M, Clifton
PM, Norman RJ and Brinkworth GD: The effect of a hypocaloric diet
with and without exercise training on body composition,
cardiometabolic risk profile and reproductive function in
overweight and obese women with polycystic ovary syndrome. J Clin
Endocrinol Metab. 93:3373–3380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Legro RS, Arslanian SA, Ehrmann DA, Hoeger
KM, Murad MH, Pasquali R and Welt CK: Endocrine Society: Diagnosis
and treatment of polycystic ovary syndrome: An Endocrine Society
clinical practice guideline. J Clin Endocrinol Metab. 98:4565–4592.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vilsbøll T, Christensen M, Junker AE, Knop
FK and Gluud LL: Effects of glucagon-like peptide-1 receptor
agonists on weight loss: Systematic review and meta-analyses of
randomised controlled trials. BMJ. 344:d77712012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Astrup A, Rössner S, Van Gaal L, Rissanen
A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF and Lean ME:
NN8022-1807 Study Group: Effects of liraglutide in the treatment of
obesity: A randomised, double-blind, placebo-controlled study.
Lancet. 374:1606–1616. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lean ME, Carraro R, Finer N, Hartvig H,
Lindegaard ML, Rössner S, Van Gaal L and Astrup A: NN8022-1807
Investigators: Tolerability of nausea and vomiting and associations
with weight loss in a randomized trial of liraglutide in obese,
non-diabetic adults. Int J Obes (Lond). 38:689–697. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jensterle M, Kravos NA, Pfeifer M, Kocjan
T and Janez A: A 12-week treatment with the long-acting
glucagon-like peptide 1 receptor agonist liraglutide leads to
significant weight loss in a subset of obese women with newly
diagnosed polycystic ovary syndrome. Hormones (Athens). 14:81–90.
2015.PubMed/NCBI
|
|
12
|
Jensterle Sever M, Kocjan T, Pfeifer M,
Kravos NA and Janez A: Short-term combined treatment with
liraglutide and metformin leads to significant weight loss in obese
women with polycystic ovary syndrome and previous poor response to
metformin. Eur J Endocrinol. 170:451–459. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bruno RV, de Avila MA, Neves FB, Nardi AE,
Crespo CM and Sobrinho AT: Comparison of two doses of metformin
(2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome
and their effect on body mass index and waist circumference. Fertil
Steril. 88:510–512. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gambineri A, Patton L, Vaccina A, Cacciari
M, Morselli-Labate AM, Cavazza C, Pagotto U and Pasquali R:
Treatment with flutamide, metformin and their combination added to
a hypocaloric diet in overweight-obese women with polycystic ovary
syndrome: A randomized, 12-month, placebo-controlled study. J Clin
Endocrinol Metab. 91:3970–3980. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harborne LR, Sattar N, Norman JE and
Fleming R: Metformin and weight loss in obese women with polycystic
ovary syndrome: Comparison of doses. J Clin Endocrinol Metab.
90:4593–4598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nieuwenhuis-Ruifrok AE, Kuchenbecker WK,
Hoek A, Middleton P and Norman RJ: Insulin sensitizing drugs for
weight loss in women of reproductive age who are overweight or
obese: Systematic review and meta-analysis. Hum Reprod Update.
15:57–68. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maida A, Lamont BJ, Cao X and Drucker DJ:
Metformin regulates the incretin receptor axis via a pathway
dependent on peroxisome proliferator-activated receptor-α in mice.
Diabetologia. 54:339–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mannucci E, Ognibene A, Cremasco F,
Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Messeri G and
Rotella CM: Effect of metformin on glucagon-like peptide 1 (GLP-1)
and leptin levels in obese nondiabetic subjects. Diabetes Care.
24:489–494. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mannucci E, Tesi F, Bardini G, Ognibene A,
Petracca MG, Ciani S, Pezzatini A, Brogi M, Dicembrini I and
Cremasco F: Effects of metformin on glucagon-like peptide-1 levels
in obese patients with and without Type 2 diabetes. Diabetes Nutr
Metab. 17:336–342. 2004.PubMed/NCBI
|
|
20
|
Yasuda N, Inoue T, Nagakura T, Yamazaki K,
Kira K, Saeki T and Tanaka I: Enhanced secretion of glucagon-like
peptide 1 by biguanide compounds. Biochem Biophys Res Commun.
298:779–784. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
American Diabetes Association: Standards
of medical care in diabetes-2013. Diabetes Care. 36(Suppl 1):
S11–S66. 2013.PubMed/NCBI
|
|
22
|
Moran LJ, Pasquali R, Teede HJ, Hoeger KM
and Norman RJ: Treatment of obesity in polycystic ovary syndrome: A
position statement of the Androgen Excess and Polycystic Ovary
Syndrome Society. Fertil Steril. 92:1966–1982. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment:
Insulin resistance and beta-cell function from fasting plasma
glucose and insulin concentrations in man. Diabetologia.
28:412–419. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dupont WD and Plummer WD Jr: Power and
sample size calculations. A review and computer program. Control
Clin Trials. 11:116–128. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alberti KGI, Zimmet P and Shaw J:
Metabolic syndrome - a new world-wide definition. A Consensus
Statement from the International Diabetes Federation. Diabet Med.
23:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Elkind-Hirsch K, Marrioneaux O, Bhushan M,
Vernor D and Bhushan R: Comparison of single and combined treatment
with exenatide and metformin on menstrual cyclicity in overweight
women with polycystic ovary syndrome. J Clin Endocrinol Metab.
93:2670–2678. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hundal RS, Krssak M, Dufour S, Laurent D,
Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF,
Landau BR and Shulman GI: Mechanism by which metformin reduces
glucose production in type 2 diabetes. Diabetes. 49:2063–2069.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Palomba S, Falbo A, Zullo F and Orio F Jr:
Evidence-based and potential benefits of metformin in the
polycystic ovary syndrome: A comprehensive review. Endocr Rev.
30:1–50. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Davies MJ, Kela R and Khunti K:
Liraglutide-overview of the preclinical and clinical data and its
role in the treatment of type 2 diabetes. Diabetes Obes Metab.
13:207–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
